PWM
ZVRA icon

Palumbo Wealth Management’s Zevra Therapeutics ZVRA Stock Holding History

Palumbo Wealth Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,902
Closed -$63.2K – 168
2024
Q2 		$63.2K Sell
12,902
-5,186
-29% -$24.6K 0.03% 145
2024
Q1 		$105K Buy
+18,088
New +$111K 0.05% 127

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Palumbo Wealth Management's ZVRA Position: Q3 2024 in Review

Palumbo Wealth Management sold out of Zevra Therapeutics (ZVRA) in Q3 2024, closing a stake of 12,902 shares — an estimated $63.2K sold.

Palumbo Wealth Management first reported a position in ZVRA in Q1 2024 and held it in 2 quarters. The position peaked at $105K in Q1 2024. 108 funds tracked by Wall St. Rank hold ZVRA as of Q3 2024.

  • Palumbo Wealth Management reported no remaining Zevra Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Palumbo Wealth Management sold 12,902 Zevra Therapeutics shares in Q3 2024, an estimated $63.2K.
  • Palumbo Wealth Management first reported a position in Zevra Therapeutics in Q1 2024 and held it in 2 quarters.
  • Palumbo Wealth Management's Zevra Therapeutics position peaked at $105K in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2024.

Based on Palumbo Wealth Management's 13F filing for Q3 2024, filed 28 Oct 2024.